Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Teva
Cantor Fitzgerald
Fish and Richardson
Citi
Colorcon

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 9,434,786

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,434,786
Title:Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
Abstract: The present invention provides for recombinant Endo-S mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor. Such recombinant Endo-S mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain to provide different antibody glycoforms carrying structurally well-defined Fc N-glycans.
Inventor(s): Wang; Lai-Xi (Ellicott City, MD), Huang; Wei (Shanghai, CN)
Assignee: UNIVERSITY OF MARYLAND, BALTIMORE (Baltimore, MD)
Application Number:14/376,248
Patent Claims:see list of patent claims

Details for Patent 9,434,786

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REOPRO abciximab INJECTABLE; INJECTION 103575 001 1994-12-22 ➤ Sign Up UNIVERSITY OF MARYLAND, BALTIMORE (Baltimore, MD) 2032-02-10 RX search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26 ➤ Sign Up UNIVERSITY OF MARYLAND, BALTIMORE (Baltimore, MD) 2032-02-10 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12 ➤ Sign Up UNIVERSITY OF MARYLAND, BALTIMORE (Baltimore, MD) 2032-02-10 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 002 1998-05-12 ➤ Sign Up UNIVERSITY OF MARYLAND, BALTIMORE (Baltimore, MD) 2032-02-10 RX search
Medimmune SYNAGIS palivizumab VIAL 103770 001 1998-06-19 ➤ Sign Up UNIVERSITY OF MARYLAND, BALTIMORE (Baltimore, MD) 2032-02-10 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Chubb
Baxter
Boehringer Ingelheim
Accenture
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.